Paolo Gisondi to Severity of Illness Index
This is a "connection" page, showing publications Paolo Gisondi has written about Severity of Illness Index.
Connection Strength
0.137
-
Low incidence rate of respiratory and viral infections over 5 years of treatment with tildrakizumab in patients with moderate-to-severe psoriasis: pooled analysis from reSURFACE 1 and reSURFACE 2 phase 3 trials. J Eur Acad Dermatol Venereol. 2021 Nov; 35(11):e709-e711.
Score: 0.031
-
Consensus on the management of patients with psoriatic arthritis in a dermatology setting. J Eur Acad Dermatol Venereol. 2018 Apr; 32(4):515-528.
Score: 0.024
-
Psoriasis and the metabolic syndrome. Clin Dermatol. 2018 Jan - Feb; 36(1):21-28.
Score: 0.024
-
Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2017 May; 31(5):774-790.
Score: 0.023
-
The clinical spectrum of COVID-19-associated cutaneous manifestations: An Italian multicenter study of 200 adult patients. J Am Acad Dermatol. 2021 05; 84(5):1356-1363.
Score: 0.008
-
Ultrasonography of the nail unit reveals quantitative and qualitative alterations in patients with psoriasis and psoriatic arthritis. Med Ultrason. 2018 May 02; 20(2):177-184.
Score: 0.006
-
Effectiveness of etanercept in children with plaque psoriasis in real practice: a one-year multicenter retrospective study. J Dermatolog Treat. 2018 May; 29(3):217-219.
Score: 0.006
-
How to improve adherence to treatment in patients with mild-to-moderate psoriasis. G Ital Dermatol Venereol. 2018 Oct; 153(5):692-697.
Score: 0.006
-
Management of long-term therapy with biological drugs in psoriatic patients with latent tuberculosis infection in real life setting. Dermatol Ther. 2017 Sep; 30(5).
Score: 0.006
-
Imaging in psoriasis and psoriatic arthritis: GRAPPA 2008. J Rheumatol. 2010 Feb; 37(2):448-52.
Score: 0.004